scholarly journals Bloodstream infection in hemodialysis patients with end-stage renal disease at Rafic Hariri University Hospital

2020 ◽  
Vol 13 (12) ◽  
pp. 2110-2111
Author(s):  
Abi Hanna Pierre ◽  
Harb Mirvate ◽  
Youssef Bou Rached Charbel
Keyword(s):  
Renal Disease ◽  
Bloodstream Infection ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
University Hospital ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Knowledge, Attitude & Perception Of Hemodialysis Patients At Cheikh Khalifa Ibn Zaid University Hospital In Casablanca About Covid 19 Disease

2020 ◽  
Vol 1 (1) ◽  
Author(s):  
Hiba El Oury ◽  
Fatim-zahra Jabrane ◽  
Mohamed Amine Khalfaoui ◽  
M Sabah ◽  
G Medkouri
Keyword(s):  
High Risk ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
The State ◽  
University Hospital ◽  
Dialysis Center ◽  
Stage Renal Disease ◽  
End Stage ◽  
The University

Introduction:  Coronavirus disease 2019: COVID 19, is a new communicable disease caused by the SARS-CoV-2 virus, which appeared in Wuhan, Hubei Province, China in December 2019, and declared a global pandemic on March 11, 2020, by the World Health Organization (WHO). This disease is generally manifested by damage to the airways, most often of a mild form, but can be complicated by acute respiratory distress syndrome. Patients with end-stage renal disease are at high risk of contracting the infection, due to their co-morbidities, the state of immunosuppression and the logistical aspect of the provision of care requiring physical movement of patients to the center dialysis.Objectives of this study: This study aims to assess the knowledge, attitude and perception, in terms of the 2019 coronavirus pandemic, of a sample of patients with chronic end-stage renal disease hemodialysis at the nephrology and dialysis center at the university hospital Cheikh Khalifa Ibn Zaid , in Casablanca, where positive COVID 19 patients were hospitalized and treated during the pandemic.Design: The investigation began after the decree of compulsory confinement and the state of health emergency by the Moroccan government. Awareness sessions, for patients and their family members, were led by nursing staff at the start of the period and during the COVID 19 pandemic. The measuring instrument used was a self-administered questionnaire, 1 month after the start of confinement, with 25 patients with chronic end-stage renal disease on hemodialysis at the rate of 3 sessions per week, at the nephrology and dialysis center at the university hospital. Sheikh Khalifa Ibn Zaid. This questionnaire was carried out after a review of the literature and included 4 headings: a) socio-demographic data b) general knowledge of COVID19 disease c) the attitude of hemodialysis patients outside and inside the dialysis center d) and their perception of this pandemic.Results : The majority of our patients were fairly well informed about the clinical presentation, the means of transmission and the prevention measures against coronavirus 2019. The means of protection were respected outside and in the university hospital center. There were no positive COVID 19 cases among our patients. Despite all the measures taken, the concern of contacting the virus was raised by most patients, especially in the hospital, during the dialysis session and in contact with medical personnel.Conclusion: Given the rapid spread and severe progression of COVID 19, it seems prudent that this profile of patients with end-stage chronic renal failure be included in high-risk populations with close medical and also psychological monitoring, tests screening and awareness and support sessions.

Depression in end-stage renal disease hemodialysis patients

2006 ◽  
Vol 2 (12) ◽  
pp. 678-687 ◽  
Author(s):  
Daniel Cukor ◽  
Rolf A Peterson ◽  
Scott D Cohen ◽  
Paul L Kimmel
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Bloodstream infection in patients with end-stage renal disease in a teaching hospital in central-western Brazil

2013 ◽  
Vol 46 (4) ◽  
pp. 426-432 ◽  
Author(s):  
Tamara Trelha Gauna ◽  
Elizete Oshiro ◽  
Yuri Correa Luzio ◽  
Anamaria Mello Miranda Paniago ◽  
Elenir Rose Jardim Cury Pontes ◽  
...  
Keyword(s):  
Renal Disease ◽  
Bloodstream Infection ◽  
Teaching Hospital ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Correlation between Calcium Phosphorus Product and Mean Arterial Pressure among Hemodialysis Patients with End Stage Renal Disease

2020 ◽  
Vol 5 (1) ◽  
Author(s):  
Muhammad Nadeem ◽  
Mansoor Abbas Qaisar ◽  
Ali Hassan Al Hakami ◽  
Fateh Sher Chattah ◽  
Muhammad Muzammil ◽  
...  
Keyword(s):  
Mean Arterial Pressure ◽  
Arterial Pressure ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Age Group ◽  
Calcium Phosphorus ◽  
The Mean ◽  
Stage Renal Disease ◽  
End Stage

Background: The mean arterial pressure serves as an expression of blood pressure in patients on chronic hemodialysis. Serum calcium phosphorus product is considered as a risk factor of vascular calcification that is associated with hypertension in the patients of end stage renal disease. The literature regarding this relationship is inconsistent therefore this study is designed to determine the correlation between calcium phosphorus product and mean arterial pressure among hemodialysis patients with end stage renal disease. Methods: A total of 110 patients of end stage renal disease on hemodialysis for at least one year, 20 to 60 years of age were included. Patients with primary or tertiary hyperparathyroidism, peripheral vascular disease, malignancy, hypertension secondary to any cause other than kidney disease were excluded. Mean arterial pressure was calculated according to the standard protocol in lying position. Blood samples for estimation of serum calcium and phosphorous were taken and was sent immediately to the laboratory for serum analysis. Results: Mean age was 44.17 ± 10.94 years. Mean calcium phosphorous product was 46.71 ± 7.36 mg/dl and mean arterial pressure was 103.61 ± 12.77 mmHg. The values of Pearson correlation co-efficient (r) were 0.863 for age group 20 to 40 years and 0.589 for age group 41 to 60 years. This strong positive correlation means that high calcium phosphorous product goes with high mean arterial pressure (and vice versa) for both the age groups. Conclusion: A strong positive relationship exists between the mean arterial pressure and calcium phosphorous product and is independent of patients’ age.

scholarly journals Analysis of Endocan Levels in Hypertensive Patients as Risk Factors of Chronic Kidney Disease

2020 ◽  
Vol 27 (1) ◽  
Author(s):  
Suryani Jamal ◽  
Uleng Bahrun ◽  
Ibrahim Abdul Samad ◽  
Fitriani Mangarengi ◽  
Hasyim Kasim ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Stage Ii ◽  
University Hospital ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Elisa Method ◽  
Cross Sectional ◽  
Stage Renal Disease ◽  
End Stage

This study aimed to analyze endocan levels as a marker of endothelial dysfunction in the control group, patients withstage I hypertension, stage II hypertension, and patients with end-stage renal disease. Endocan levels were measured withESM-1 (endocan) kit by Enzyme-Linked Immunosorbent Assay (ELISA) method. This study used a cross-sectional methodand was conducted in Dr. Wahidin Sudirohusodo Hospital, Makassar and Hasanuddin University Hospital from Septemberto October 2017. There were 83 samples in this study, consisting of 12 samples in the control group, 22 samples of stage Ihypertension, 28 samples of stage II hypertension, and 21 samples of end-stage renal disease aged 20-90 years old. Thisstudy showed significantly higher endocan levels in patients with stage II hypertension and end-stage renal disease(p< 0.05). Endocan levels were significantly higher (p<0.05) in patients with end-stage renal disease compared with thecontrol group and patients with stage I hypertension; but not significantly higher (p > 0.05) compared to patients with stageII hypertension. Also, the median of endocan levels in patients with the end-stage renal disease was higher (309,850 ng/L)compared to patients with stage II hypertension (273,050 ng/L).

scholarly journals SP315ARCHITECT HEPATITIS C VIRUS (HCV) CORE ANTIGEN TEST: A HCV RNA SCREENING ALTERNATIVE IN END-STAGE RENAL DISEASE (ESRD) AND HEMODIALYSIS PATIENTS?

2018 ◽  
Vol 33 (suppl_1) ◽  
pp. i450-i450
Author(s):  
Rita Valério Alves ◽  
Rita Abrantes ◽  
Hernâni Gonçalves ◽  
Maria Leonor Gonçalves ◽  
Karina Lopes ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Core Antigen ◽  
Hcv Rna ◽  
Antigen Test ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals SUN-205 Prevalence of Cancer in End Stage Renal Disease Hemodialysis Patients

2020 ◽  
Vol 5 (3) ◽  
pp. S285
Author(s):  
F. AlKindi ◽  
S. Jamil ◽  
S. AlKaabi ◽  
M. Hakim ◽  
A. Chaaban ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Stage Renal Disease ◽  
End Stage ◽  
Prevalence Of Cancer

Influence of Recombinant Human Erythropoietin Therapy on Plasma Endothelin-1 Levels during Hemodialysis

2001 ◽  
Vol 24 (6) ◽  
pp. 367-373 ◽  
Author(s):  
I. Stefanidis ◽  
P.R. Mertens ◽  
P. Wurth ◽  
R. Bach ◽  
W. Makropoulos ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Recombinant Erythropoietin ◽  
Human Recombinant Erythropoietin ◽  
Endothelin 1 ◽  
Human Erythropoietin ◽  
Replacement Treatment ◽  
Stage Renal Disease ◽  
End Stage

The correction of anemia with human recombinant erythropoietin (rHuEPO) in end stage renal disease is associated with hypertension in about one third of hemodialysis patients. The pathogenesis of the rHuEPO-induced hypertension is still uncertain, though evidence of the involvement of endothelial cells has emerged. The aim of this study was to determine plasma endothelin-1 during hemodialysis and to compare the endothelin-1 levels in hemodialysis patients with and without rHuEPO substitution. Nineteen stable patients (13 male and 6 female, mean age 62 ± 11 years) with end stage renal disease were studied. Cuprophan dialysers (GFS 12®, Gambro, Lund, Sweden) were used for hemodialysis in all cases. rHuEPO (40U/kg s.c.) was administered to 10 patients. Blood pressure (BP; RR mmHg) and blood volume changes (ΔBV; hemoglobinometry %) were serially measured. Samples were taken before and every hour during hemodialysis. Plasma endothelin-1 was measured by ELISA (R&D Systems, Minneapolis, USA) and corrected for hemoconcentration. Endothelin-1 concentration was elevated before commencement of hemodialysis (1.16 ± 0.36 pg/ml) when compared to healthy controls (ref. 0.3 - 0.9) and increased to 1.47 ± 0.51 pg/ml by the end of the session (p<0.05). In patients under rHuEPO-substitution plasma endothelin-1 was higher when compared to patients without substitution before (1.25 ± 0.3 vs. 1.05 ± 0.3 pg/ml) and at the end of HD (1.62 ± 0.5 vs. 1.28 ± 0.3 pg/ml, p<0.05). There was no difference in BP and ΔBV between the two groups during treatment. Plasma endothelin-1 was higher in hemodialysis patients and there was a continuous rise in plasma endothelin-1 during a session. Comparison of two groups of hemodialysis patients with and without s.c. rHuEPO-replacement treatment revealed a significantly higher plasma endothelin-1 concentration in patients with s.c. rHuEPO treatment. However, the elevated endothelin-1 levels were not accompanied by arterial hypertension.

Sign in / Sign up

Export Citation Format

Share Document